Enoxaparin sodium

Generic Name: Enoxaparin sodium

Brand Names: Lovenox, Inhixa

Drug Type: Small Molecule

CAS Number: 9005-49-6

Unique Ingredient Identifier: E47C0NF7LV

Background: Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the incidence of venous thromboembolism in hospitalized patients when compared to unfractionated heparin, without increasing the risk of serious bleeding.

Indication: Enoxaparin is indicated for the prevention of ischemic complications in unstable angina and in non Q-wave myocardial infarction; it is indicated in conjunction with percutaneous intervention and/or other treatment for the management of acute ST elevation myocardial infarction.

Enoxaparin is also indicated in the prophylaxis of DVT in abdominal surgery, hip replacement, knee replacement, or medical patients with severely restricted mobility during acute illness. Additionally, enoxaparin is indicated for the inpatient treatment of DVT with or without pulmonary embolism and the treatment of outpatient DVT without pulmonary embolism.

Associated Conditions: Acute Coronary Syndrome (ACS), Acute Myocardial Infarction With ST Segment Elevation, Deep Vein Thrombosis, Ischemic complications caused by non-q wave myocardial infarction, Ischemic complications caused by unstable angina

Associated Therapies: Percutaneous Coronary Intervention (PCI)

Clinical Trials

Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients With Restricted Mobility

Phase 3

Terminated

Conditions: Venous Thromboembolism

Interventions: Drug: Semuloparin sodium
Drug: Enoxaparin sodium

First Posted Date: 2008-07-14

Last Posted Date: 2013-01-23

Lead Sponsor: Sanofi

Target Recruit Count: 421

Registration Number: NCT00714597

Locations: 🇬🇧
Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom
🇦🇺
sanofi-aventis Australia & New Zealand administrative office, Macquarie Park, New South Wales, Australia

Prevention of Venous Thromboembolism in Patients With Acute Primary Intracerebral Hemorrhage

Phase 4

Conditions: Intracerebral Hemorrhage

Interventions: Drug: enoxaparin placebo
Drug: enoxaparin

First Posted Date: 2008-06-18

Last Posted Date: 2010-07-02

Lead Sponsor: University of Oulu

Target Recruit Count: 320

Registration Number: NCT00699465

Locations: 🇫🇮
Department of Neurology, Oulu University Hospital, Oulu, Finland

Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement Surgery

Phase 3

Completed

Conditions: Venous Thromboembolism

Interventions: Drug: Semuloparin sodium
Drug: Enoxaparin sodium
Drug: Placebo

First Posted Date: 2008-06-13

Last Posted Date: 2013-01-23

Lead Sponsor: Sanofi

Target Recruit Count: 2326

Registration Number: NCT00697099

Locations: 🇦🇺
sanofi-aventis Australia & New Zealand administrative office, Macquarie Park, New South Wales, Australia
🇨🇳
Sanofi-Aventis Administraive Office, Taipei, Taiwan
🇺🇦
Sanofi-Aventis Administrative Office, Kiev, Ukraine

Japanese Safety and Efficacy Study of Enoxaparin in Patients With Hip Fracture Surgery

Phase 3

Completed

Conditions: Hip Fractures

First Posted Date: 2008-05-29

Last Posted Date: 2009-10-02

Lead Sponsor: Sanofi

Target Recruit Count: 54

Registration Number: NCT00685958

Locations: 🇯🇵
Sanofi- Aventis Administrative Office, Tokyo, Japan

Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery

Phase 3

Completed

Conditions: Venous Thromboembolism

Interventions: Drug: Semuloparin Sodium
Drug: Enoxaparin sodium
Drug: Placebo

First Posted Date: 2008-05-19

Last Posted Date: 2013-12-16

Lead Sponsor: Sanofi

Target Recruit Count: 4413

Registration Number: NCT00679588

Locations: 🇺🇸
Investigational Site Number 840036, Springfield, Illinois, United States
🇺🇸
Investigational Site Number 840007, Huntingdon Beach, California, United States
🇺🇸
Investigational Site Number 840017, Jacksonville, Florida, United States

and more 267 locations

Anticoagulant Treatments and Percutaneous Coronary Angioplasty

Phase 4

Terminated

Conditions: Coronary Artery Disease

Interventions: Drug: heparin + clopidogrel + aspirin
Drug: bivalirudin + clopidogrel + aspirin
Drug: clopidogrel + aspirin
Drug: enoxaparin + clopidogrel + aspirin

First Posted Date: 2008-04-29

Last Posted Date: 2019-05-17

Lead Sponsor: Centre Hospitalier de PAU

Target Recruit Count: 99

Registration Number: NCT00669149

Locations: 🇫🇷
Centre Hospitalier de Pau, PAU, Pyrénées-Atlantiques, France

Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty

Phase 3

Completed

Conditions: Venous Thromboembolism

Interventions: Drug: Enoxaparin
Drug: Dabigatran etexilate

First Posted Date: 2008-04-14

Last Posted Date: 2014-07-02

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 2055

Registration Number: NCT00657150

Locations: 🇺🇸
1160.64.01003 Boehringer Ingelheim Investigational Site, Missoula, Montana, United States
🇺🇸
1160.64.01002 Boehringer Ingelheim Investigational Site, Houston, Texas, United States
🇨🇦
1160.64.6011 Boehringer Ingelheim Investigational Site, Oshawa, Ontario, Canada

and more 105 locations

Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism

Phase 3

Completed

Conditions: Venous Thrombosis

Interventions: Drug: Enoxaparin
Drug: Placebo for enoxaparin
Drug: Placebo for warfarin
Drug: warfarin
Drug: Placebo for apixaban
Drug: apixaban

First Posted Date: 2008-03-26

Last Posted Date: 2014-04-21

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 5614

Registration Number: NCT00643201

Locations: 🇺🇸
Pasadena Center For Medical Research, St. Petersburg, Florida, United States
🇺🇸
Great Falls Clinic, Llp, Great Falls, Montana, United States
🇺🇸
Infectious Disease Of Indiana Psc, Carmel, Indiana, United States

and more 71 locations